NR1D1 and prostate adenocarcinoma: Many studies including our study here demonstrate that anti-AR therapies, including Enzalutamide, Apalutamide, Bicalutamide, and Darolutamide, can induce LP in prostate adenocarcinoma, highlighting a potential adaptive response that may contribute to therapy resistance, suggesting that combining ARSIs with targeted interventions that block LP, such as inhibition of key regulators like REV-ERBα, may improve therapeutic outcomes and prevent ARSI resistance.